Fostering efficacy of anti &NDASH; PD-1 &NDASH; treatment: Nivolumab plus radiotherapy in advanced NSCLC.
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms FORCE
- 08 Aug 2017 Status changed from not yet recruiting to recruiting.
- 26 Dec 2016 New trial record